A Phase I/II, Open-Label, Dose Escalation Followed by Single-Arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

被引：0
|
作者：
Ronen, O. [1 ]
Shickler, M. [2 ]
Reuveni, H. [2 ]
Israel, I. [2 ]
Haviv, I. [2 ]
Waymack, P. J. [2 ]
Cohen, E. [3 ]
机构：
[1] Galilee Med Ctr, Nahariyya, Israel
[2] Kitov Pharma, Tel Aviv, Israel
[3] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2020年 / 106卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
312
引用
收藏
页码：1182 / 1183
页数：2
相关论文
共 50 条
  • [21] A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover
    Cupissol, Didier
    Seiwert, Tanguy Y.
    Fayette, Jerome
    Ehrnrooth, Eva
    Blackman, Alice Sarah
    Cong, Xiuyu Julie
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Roe, Denise
    Saba, Nabil F.
    Bauman, Jessica Ruth
    Kaczmar, John M.
    Burtness, Barbara
    Muzaffar, Jameel
    Julian, Ricklie Ann
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor Ernst
    Bhatia, Aarti K.
    Giri, Anshu
    Caulin, Carlos
    Stabile, Laura P.
    Centuori, Sara
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
    Chung, Christine H.
    Bonomi, Marcelo Raul
    Steuer, Conor Ernst
    Schell, Michael J.
    Li, Jiannong
    Johnson, Matthew
    Masannat, Jude
    Hernandez-Prera, Juan C.
    McMullen, Caitlin
    Wadsworth, J.
    Patel, Krupal
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Bourhis, Jean
    Rivera, Fernando
    Mesia, Ricard
    Awada, Ahmad
    Geoffrois, Lionel
    Borel, Christian
    Humblet, Yves
    Lopez-Pousa, Antonio
    Hitt, Ricardo
    Vega Villegas, M. Eugenia
    Duck, Lionel
    Rosine, Dominique
    Amellal, Nadia
    Schueler, Armin
    Harstrick, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2866 - 2872
  • [25] An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.
    Sacco, Assuntina Gesualda
    Chen, Ruifeng
    Ghosh, Debanjali
    Wong, Deborah J. L.
    Worden, Francis P.
    Adkins, Douglas
    Pittman, Emily
    Messer, Karen
    Gold, Kathryn A.
    Daniels, Gregory A.
    Swiecicki, Paul
    Sutton, Brian
    Natsuhara, Amanda
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
    Bossi, P.
    Merlano, M. C.
    Ghi, M. G.
    Rinaldi, G.
    Caponigro, F.
    Morelli, F.
    Airoldi, M.
    Farnesi, A.
    Cassano, A.
    Ferrari, D.
    Mirabile, A.
    Tosoni, A.
    Galizia, D.
    Moretti, G.
    Sponghini, A. P.
    Calareso, G.
    Vingiani, A.
    Perrone, F.
    Falletta, A.
    Licitra, L. F.
    ANNALS OF ONCOLOGY, 2019, 30 : 463 - 463
  • [27] Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Chung, Christine H.
    Saba, Nabil F.
    Steuer, Conor Ernst
    Li, Jiannong
    Bhateja, Priyanka
    Johnson, Matthew
    Masannat, Jude
    Poole, Maria
    Hoening, Dirk
    Song, Feifei
    Hernandez-Prera, Juan C.
    Molina, Helen
    Wenig, Bruce
    Farinhas, Joaquim
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Schell, Michael J.
    Bonomi, Marcelo Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial
    Guo, Ye
    Shi, Mei
    Yang, Ankui
    Feng, Jifeng
    Zhu, Xiaodong
    Choi, Young-Jin
    Hu, Guoqin
    Pan, Jianji
    Hu, Chunhong
    Luo, Rongcheng
    Zhang, Yiping
    Zhou, Liang
    Cheng, Ying
    Luepfert, Christian
    Cai, Junliang
    Shi, yuankai
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (08): : 1081 - 1087
  • [29] Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study
    Bruce, Justine Yang
    Burr, Adam
    Kimple, Randall J.
    Adam, David P.
    Yu, Menggang
    Piaskowski, Shari M.
    Glazer, Tiffany A.
    Hill, Patrick
    Hartig, Gregory K.
    Mcculloch, Timothy M.
    Wieland, Aaron M.
    Trask, Diana
    Oliver, Kate
    Longcor, Jarrod
    Rogus-Pulia, Nicole
    Cho, Steve Y.
    Bednarz, Bryan
    Harari, Paul M.
    EBIOMEDICINE, 2025, 111
  • [30] Safety and efficacy of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II study
    Guo, Y.
    Li, D. Z.
    Lin, J.
    Sun, C.
    Cao, G.
    Wu, J.
    Ge, M.
    Hu, D.
    Qu, S.
    Shen, L.
    Wei, Y.
    Zong, J.
    Fang, M.
    Jin, C.
    Li, Z-M.
    Sun, Y.
    Wang, X.
    Zhang, H.
    Wang, W.
    Zhu, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S625 - S625
12345